The finding that causes of abnormal ALT level (31 IU/L or above) in a majority of Japanese diabetic patients may be associated with NAFLD [42] implies that the efficacy of SGLT2 inhibitor on NASH/NAFLD patients can be expected. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.